<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01780519</url>
  </required_header>
  <id_info>
    <org_study_id>12-006469</org_study_id>
    <nct_id>NCT01780519</nct_id>
  </id_info>
  <brief_title>The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms</brief_title>
  <official_title>The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' goal is to determine if certain tests of memory and attention, performed
      while sleepiness is induced by a single dose of lorazepam, can predict whether or not an
      individual is at risk for developing Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Groton Maze Learning Test (GMLT) score</measure>
    <time_frame>baseline to 5 hours</time_frame>
    <description>The GMLT assesses visuospatial working memory, error monitoring, information processing speed, and short-term delayed recall for a complex hidden maze. Subjects are familiarized with the task during two untimed practice tests, and once the tester is confident that the subject understands the rules and can move easily around the grid, the timed test is administered. In each of the 5 successive trials of the GMLT exam, the subject is asked to learn to navigate his or her way around a 28-step maze that is hidden beneath a 10 x 10 grid of squares on the computer touch screen. For each trial, the time to completion, number of correct moves, number of wrong moves, and the number of perseverative errors are recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Auditory Verbal Learning Test (AVLT) Long-term memory score</measure>
    <time_frame>baseline to 5 hours</time_frame>
    <description>The AVLT assesses verbal memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two Back Test (TBK)</measure>
    <time_frame>baseline to 5 hours</time_frame>
    <description>The TBK measures working memory</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Alzheimer's Disease (AD)</condition>
  <arm_group>
    <arm_group_label>L/VL APOE e3/e4 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L/S APOE e3/e4 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>long and short poly - T variants of TOMM40 and APOE e3/e4 carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S/VL APOE e3/e3 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VL/VL APOE e3/e3 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Very long poly - T variants of TOMM40 and APOE e3/e3 carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S/S APOE e3/e3 carrier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>short poly - T variants of TOMM40 and APOE e3/e3 carrier</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorazepam</intervention_name>
    <description>single dose of 1 mg lorazepam</description>
    <arm_group_label>L/VL APOE e3/e4 carrier</arm_group_label>
    <arm_group_label>L/S APOE e3/e4 carrier</arm_group_label>
    <arm_group_label>S/VL APOE e3/e3 carrier</arm_group_label>
    <arm_group_label>VL/VL APOE e3/e3 carrier</arm_group_label>
    <arm_group_label>S/S APOE e3/e3 carrier</arm_group_label>
    <other_name>Ativan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Mini-Mental State Examination (MMSE) score of 28-30

          -  Hamilton Depression Rating Scale score of less than 10

          -  participants in longitudinal study of aging and have a TOMM40 genotype of S/S, VL/VL,
             S/VL, L/S or L/VL.

        Exclusion criteria:

          -  Alzheimer's Disease or Mild Cognitive Impairment

          -  any significant medical, psychiatric, and neurological illnesses, e.g., impaired liver
             or kidney function, prior stroke, traumatic brain injury, memory impairment, cognitive
             impairment, parkinsonism, a lifetime history of schizophrenia, bipolar disorder, a
             psychoactive substance use disorder, or current major depression.

          -  known allergy to benzodiazepines

          -  current use (within the previous four weeks) of benzodiazepines or other medications
             known to interact with lorazepam, current use of sedating antihistamines, or current
             use of stimulant medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Stonnington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2013</study_first_submitted>
  <study_first_submitted_qc>January 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2013</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Cynthia M. Stonnington, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's disease (AD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

